| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30068105 | HIV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS30068106 | HIV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20062080 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20061501 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20023329 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20038182 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20061739 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20043130 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CHRM2 |
|---|---|
| DrugBank ID | DB01062 |
| Drug Name | Oxybutynin |
| Target ID | BE0000560 |
| UniProt ID | P08172 |
| Regulation Type | antagonist |
| PubMed IDs | 15963006; 16188951; 19446545; 20590605; 17222678; 7620236 |
| Citations | Dmochowski R: Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf. 2005;28(7):583-600.@@Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27.@@Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13.@@Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x.@@Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70.@@Yarker YE, Goa KL, Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007. |
| Groups | Approved; Investigational |
| Direct Classification | Benzene and substituted derivatives |
| SMILES | CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1 |
| Pathways | |
| PharmGKB | PA164746030 |
| ChEMBL | CHEMBL1231 |
